Coagulation Products and Their Uses
The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed.
Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to antihemophilic factor (AHF) cannot spontaneously stop an acute hemorrhage. Coagulation products used to manage bleeding in patients with these disorders include AHF concentrates, factor IX concentrates, factor VIIa concentrate, factor IX complexes, anti-inhibitor coagulant complexes, and desmopressin acetate. Typically, these commercially available products are used to manage acute bleeding or to prevent excessive bleeding during surgery. The dosage of the coagulation products and the duration of therapy depend on many variables, including the severity of the hemorrhage, the pharmacokinetics of the coagulation products, and patient-specific factors. Product purity and viral attenuation are also important considerations in determining an appropriate dosage regimen. Recombinant versions of some coagulant factors are available and can eliminate the risk of viral transmission.
A thorough understanding of each coagulation product can guide product selection, dosing, and treatment duration and can reduce the risk of viral transmission.
A number of coagulation products are available to replace the absent or nonfunctional coagulation factors in persons with congenital or acquired coagulation disorders. Some products are harvested from humans or animals, and some are manufactured by using recombinant technology. Antihemophilic factor (AHF, or factor VIII), factor IX, factor VIIa, factor IX complexes, anti-inhibitor coagulant complexes, and desmopressin acetate may be used to treat hemophilia, von Willebrand's disease (VWD), or acquired AHF inhibitors. This article reviews the indications, pharmacokinetics, and therapeutic guidelines for currently available coagulation products.
Abstract and Introduction
Abstract
The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed.
Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to antihemophilic factor (AHF) cannot spontaneously stop an acute hemorrhage. Coagulation products used to manage bleeding in patients with these disorders include AHF concentrates, factor IX concentrates, factor VIIa concentrate, factor IX complexes, anti-inhibitor coagulant complexes, and desmopressin acetate. Typically, these commercially available products are used to manage acute bleeding or to prevent excessive bleeding during surgery. The dosage of the coagulation products and the duration of therapy depend on many variables, including the severity of the hemorrhage, the pharmacokinetics of the coagulation products, and patient-specific factors. Product purity and viral attenuation are also important considerations in determining an appropriate dosage regimen. Recombinant versions of some coagulant factors are available and can eliminate the risk of viral transmission.
A thorough understanding of each coagulation product can guide product selection, dosing, and treatment duration and can reduce the risk of viral transmission.
Introduction
A number of coagulation products are available to replace the absent or nonfunctional coagulation factors in persons with congenital or acquired coagulation disorders. Some products are harvested from humans or animals, and some are manufactured by using recombinant technology. Antihemophilic factor (AHF, or factor VIII), factor IX, factor VIIa, factor IX complexes, anti-inhibitor coagulant complexes, and desmopressin acetate may be used to treat hemophilia, von Willebrand's disease (VWD), or acquired AHF inhibitors. This article reviews the indications, pharmacokinetics, and therapeutic guidelines for currently available coagulation products.
Source...